Skip to main content
MyPeptideMatch logoMyPeptideMatch
Reviewed by MyPeptideMatch Editorial TeamLast reviewed February 2026Updated February 2026

Crystagen Dosing Protocol: 20 mg Vial — Immune System Bioregulator Guide

Crystagen (Lys-Glu-Asp tripeptide) Russian immune system bioregulator dosing guide — thymus function normalization, T-cell activation, and immune aging reversal.

Quickstart highlights

Crystagen (Lys-Glu-Asp, KED) is a short peptide bioregulator derived from thymus tissue, developed by Khavinson.

  • Concentration: 2 mg/mL. At 2 mg/mL: 200 µg = 10 units daily x 10 days.
  • Target: thymic epithelial cell gene normalization → improved T-cell output.
  • One 20 mg vial = 100 doses; 10 complete 10-day courses from one vial.
  • Pair with Thymosin Alpha-1 for enhanced T-cell activation from two complementary mechanisms.
  • Particularly relevant for immunosenescent individuals aged 50+.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1-2 (10-day course)20010Once daily200 µg — 10 units; 10-day intensive course
Maintenance20010Every other day200 µg EOD — immune maintenance

Reconstitution steps

  1. Reconstitute in 2.5 mL bac water portions; inject slowly down vial wall.
  2. Swirl gently until dissolved. Final concentration: 2 mg/mL.
  3. Label with date; refrigerate 2–8 °C. Use within 28 days.

Supplies needed

10_day-week plan

  • 1 vial
  • 10 syringes
  • 2 mL bac water
  • 10 alcohol swabs
Need clinics? See vetted providers →

Protocol overview & cycle notes

Normalize thymic T-cell maturation, reduce immunosenescence, and enhance innate and adaptive immunity through the Crystagen tripeptide immune bioregulator 10-day intensive course.

Off-cycle: 4–6 months between intensive courses.

Storage & handling

Lyophilized: store below 25 °C. Reconstituted: refrigerate 2–8 °C; use within 28 days.

Injection & tracking tips

  • Inject subcutaneously at any time of day.
  • Crystagen targets thymus involution reversal — particularly relevant for immunosenescent individuals (>50 years).
  • Combine with Thymosin Alpha-1 for comprehensive T-cell immune augmentation.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • CD4/CD8 T-cell ratio and NK cell activity at baseline and 3 months.
  • Track frequency of infections (respiratory, urinary, etc.) per quarter.
  • Log subjective immune resilience (ability to fight illness) (0–10) monthly.
Log your cycle in the calculator →

How this works & references

Crystagen (Lys-Glu-Asp, KED) is a short peptide bioregulator derived from thymus tissue, developed by Khavinson. The thymus involutes with aging, reducing naive T-cell output and contributing to immunosenescence (the progressive deterioration of immune function with age). Crystagen is proposed to normalize thymic epithelial cell gene expression, potentially restoring thymic output and T-cell repertoire diversity. Russian clinical applications include immunosenescence prevention, recurrent infection management, and post-chemotherapy immune restoration. Khavinson group data shows improved CD3+ and CD4+ T-cell counts after Crystagen courses in aging patients.

Sources

  • Source: Khavinson VK et al. — Immune bioregulators and thymic involution. Ann Gerontol. 2003

Frequently asked questions

How is Crystagen different from Thymosin Alpha-1 for immunity?
Thymosin Alpha-1 is an exogenous thymic hormone that directly activates T-cell, NK cell, and dendritic cell function acutely. Crystagen is a gene expression normalizer that targets thymic epithelial cells — attempting to restore the thymus's capacity to produce T-cells rather than directly activating existing T-cells. Crystagen's action is slower and more structural; TA1's action is more immediate and systemic.
Can Crystagen reverse thymic involution?
Full thymic regeneration (restoration of cortical/medullary architecture) is unlikely from a short peptide bioregulator. Partial restoration of thymic epithelial cell function — improved expression of thymic epithelial-specific genes (FOXN1, DLL4) — is the proposed mechanism. This may increase naive T-cell output marginally rather than restoring a youthful thymus.
Who benefits most from Crystagen?
Based on the immunosenescence targeting: individuals aged 50+ with declining immune function, recurrent infections, or post-cancer immune depletion. Cancer patients post-chemotherapy (with depleted T-cell pools) are another common application in Russian integrative oncology protocols.
Can Crystagen be combined with Epithalon?
Yes — Epithalon (pineal bioregulator/telomerase) + Crystagen (immune/thymic bioregulator) is a complementary combination for comprehensive anti-aging: Epithalon targets cellular longevity mechanisms; Crystagen targets immune system aging. Both use the same 10-day course format and can be alternated (different course periods) or combined in the same course.
Are there contraindications to Crystagen?
Theoretical caution in active autoimmune disease — T-cell augmentation could worsen T-cell-mediated autoimmunity (MS, rheumatoid arthritis, type 1 diabetes). As with all bioregulators, the mechanism is claimed to be normalizing rather than purely stimulating, but clinical evidence in autoimmune populations is absent. Use with specialist guidance in autoimmune conditions.

Related protocols

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.